Abstract

Forty percent of the cells within GM-CSF mobilized peripheral stem cell products (PSC) ire CD14+ which following isolation are directly associated with a suppressor cell function. These cells suppress T cell responses to PHA, pokeweed mitogen, IL-2 and IL-12. However, their removal from PSC products restores T cell function and proliferative capacity. The suppressor cells are low density, adherent and phagocytic; in addition to HLA-DR+, CD4+, CD11a+, CD11b+, CD86 (B7.2)+, CD80 (B7.1)-, CD16- and CD1a- suggesting that they are either monocyte or monocyte-dendritic cell precursors. Following 7 days of incubation with TNF and GM-CSF, cells remain CD14+CD1a- but go from CD86+ to CD80+ while retaining suppressor cell activity suggesting a true monocytic origin. Cell-cell contact is required for suppression (paraformaldehyde treated CD14 cells are suppressive) and is not neutralized by antibodies directed against TNF. The PSC products have increased mRNA levels for IL-10, IL-4, IL-8, IL-2, TNF and IFN-γ compared to normal PBL; although the IL-10 is associated with CD14+ and not T cells. The suppressor cell activity has potential to regulate immune recovery following myeloablative therapy and the removal of these cells from the PSC has therapeutic potential. Further, they may reduce immunologie and therapeutic responses to adjuvant immunotherapy, conversely, suppressor cells have clinical potential for allogeneic graft-versushost disease or solid organ graft rejection.

Original languageEnglish (US)
Number of pages1
JournalExperimental Hematology
Volume24
Issue number9
StatePublished - Dec 1 1996

Fingerprint

Stem Cells
Cytokines
Granulocyte-Macrophage Colony-Stimulating Factor
T-Lymphocytes
Interleukin-10
Interleukin-2
Monocytes
Transplants
Pokeweed Mitogens
Graft Rejection
HLA-DR Antigens
Interleukin-12
Cell- and Tissue-Based Therapy
Interleukin-8
Interleukin-4
Immunotherapy
Dendritic Cells
Cell Count
Messenger RNA
Peripheral Blood Stem Cells

ASJC Scopus subject areas

  • Cancer Research
  • Cell Biology
  • Genetics
  • Hematology
  • Oncology
  • Transplantation

Cite this

Cd14+ suppressor cells in cytokine mobilized stem cell products. / Talmadge, James E; Singh, Rakesh K; Ageitos, A.; Ozerol, I.; Ino, K.

In: Experimental Hematology, Vol. 24, No. 9, 01.12.1996.

Research output: Contribution to journalArticle

@article{79c0b9dd5bf442539c440fada6a73662,
title = "Cd14+ suppressor cells in cytokine mobilized stem cell products",
abstract = "Forty percent of the cells within GM-CSF mobilized peripheral stem cell products (PSC) ire CD14+ which following isolation are directly associated with a suppressor cell function. These cells suppress T cell responses to PHA, pokeweed mitogen, IL-2 and IL-12. However, their removal from PSC products restores T cell function and proliferative capacity. The suppressor cells are low density, adherent and phagocytic; in addition to HLA-DR+, CD4+, CD11a+, CD11b+, CD86 (B7.2)+, CD80 (B7.1)-, CD16- and CD1a- suggesting that they are either monocyte or monocyte-dendritic cell precursors. Following 7 days of incubation with TNF and GM-CSF, cells remain CD14+CD1a- but go from CD86+ to CD80+ while retaining suppressor cell activity suggesting a true monocytic origin. Cell-cell contact is required for suppression (paraformaldehyde treated CD14 cells are suppressive) and is not neutralized by antibodies directed against TNF. The PSC products have increased mRNA levels for IL-10, IL-4, IL-8, IL-2, TNF and IFN-γ compared to normal PBL; although the IL-10 is associated with CD14+ and not T cells. The suppressor cell activity has potential to regulate immune recovery following myeloablative therapy and the removal of these cells from the PSC has therapeutic potential. Further, they may reduce immunologie and therapeutic responses to adjuvant immunotherapy, conversely, suppressor cells have clinical potential for allogeneic graft-versushost disease or solid organ graft rejection.",
author = "Talmadge, {James E} and Singh, {Rakesh K} and A. Ageitos and I. Ozerol and K. Ino",
year = "1996",
month = "12",
day = "1",
language = "English (US)",
volume = "24",
journal = "Experimental Hematology",
issn = "0301-472X",
publisher = "Elsevier Inc.",
number = "9",

}

TY - JOUR

T1 - Cd14+ suppressor cells in cytokine mobilized stem cell products

AU - Talmadge, James E

AU - Singh, Rakesh K

AU - Ageitos, A.

AU - Ozerol, I.

AU - Ino, K.

PY - 1996/12/1

Y1 - 1996/12/1

N2 - Forty percent of the cells within GM-CSF mobilized peripheral stem cell products (PSC) ire CD14+ which following isolation are directly associated with a suppressor cell function. These cells suppress T cell responses to PHA, pokeweed mitogen, IL-2 and IL-12. However, their removal from PSC products restores T cell function and proliferative capacity. The suppressor cells are low density, adherent and phagocytic; in addition to HLA-DR+, CD4+, CD11a+, CD11b+, CD86 (B7.2)+, CD80 (B7.1)-, CD16- and CD1a- suggesting that they are either monocyte or monocyte-dendritic cell precursors. Following 7 days of incubation with TNF and GM-CSF, cells remain CD14+CD1a- but go from CD86+ to CD80+ while retaining suppressor cell activity suggesting a true monocytic origin. Cell-cell contact is required for suppression (paraformaldehyde treated CD14 cells are suppressive) and is not neutralized by antibodies directed against TNF. The PSC products have increased mRNA levels for IL-10, IL-4, IL-8, IL-2, TNF and IFN-γ compared to normal PBL; although the IL-10 is associated with CD14+ and not T cells. The suppressor cell activity has potential to regulate immune recovery following myeloablative therapy and the removal of these cells from the PSC has therapeutic potential. Further, they may reduce immunologie and therapeutic responses to adjuvant immunotherapy, conversely, suppressor cells have clinical potential for allogeneic graft-versushost disease or solid organ graft rejection.

AB - Forty percent of the cells within GM-CSF mobilized peripheral stem cell products (PSC) ire CD14+ which following isolation are directly associated with a suppressor cell function. These cells suppress T cell responses to PHA, pokeweed mitogen, IL-2 and IL-12. However, their removal from PSC products restores T cell function and proliferative capacity. The suppressor cells are low density, adherent and phagocytic; in addition to HLA-DR+, CD4+, CD11a+, CD11b+, CD86 (B7.2)+, CD80 (B7.1)-, CD16- and CD1a- suggesting that they are either monocyte or monocyte-dendritic cell precursors. Following 7 days of incubation with TNF and GM-CSF, cells remain CD14+CD1a- but go from CD86+ to CD80+ while retaining suppressor cell activity suggesting a true monocytic origin. Cell-cell contact is required for suppression (paraformaldehyde treated CD14 cells are suppressive) and is not neutralized by antibodies directed against TNF. The PSC products have increased mRNA levels for IL-10, IL-4, IL-8, IL-2, TNF and IFN-γ compared to normal PBL; although the IL-10 is associated with CD14+ and not T cells. The suppressor cell activity has potential to regulate immune recovery following myeloablative therapy and the removal of these cells from the PSC has therapeutic potential. Further, they may reduce immunologie and therapeutic responses to adjuvant immunotherapy, conversely, suppressor cells have clinical potential for allogeneic graft-versushost disease or solid organ graft rejection.

UR - http://www.scopus.com/inward/record.url?scp=33748605887&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748605887&partnerID=8YFLogxK

M3 - Article

VL - 24

JO - Experimental Hematology

JF - Experimental Hematology

SN - 0301-472X

IS - 9

ER -